Profusa (NASDAQ:PFSA) Shares Set to Reverse Split on Monday, February 9th

Profusa, Inc. (NASDAQ:PFSAFree Report)’s stock is going to reverse split on the morning of Monday, February 9th. The 1-75 reverse split was announced on Thursday, February 5th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, February 6th.

Profusa Trading Down 36.4%

PFSA stock traded down $0.03 during trading on Thursday, reaching $0.05. 14,921,879 shares of the company were exchanged, compared to its average volume of 16,309,144. The firm’s 50 day moving average is $0.11. The stock has a market cap of $4.74 million, a P/E ratio of -0.02 and a beta of -0.14. Profusa has a 52-week low of $0.05 and a 52-week high of $2.40.

Profusa (NASDAQ:PFSAGet Free Report) last posted its earnings results on Wednesday, November 19th. The company reported ($0.70) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Profusa in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Read Our Latest Research Report on Profusa

Profusa Company Profile

(Get Free Report)

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.

Featured Articles

Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.